Editor's Choice
REVIEW PAPER
Lessons learned from 2001–2021 – from the bioterrorism to the pandemic era
 
More details
Hide details
1
1st Clinical Military Hospital with Outpatient Clinic, Lublin, Poland
2
Department of Epidemiology and Biostatistic, Medical University, Warsaw, Poland
3
Biological Threats Identification and Countermeasurs Centre of the Military Institute of Hygiene and Epidemiology, Puławy, Poland
CORRESPONDING AUTHOR
Aleksander Michalski   

1st Clinical Military Hospital with Outpatient Clinic, Racławickei 23, Lublin, Poland
 
Ann Agric Environ Med. 2022;29(1):1–11
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
The aim of the study was to analyze available literature on the development of biological warfare and combating the SARS CoV-2 pandemic. Against the background of contemporary threats from biological factors, the strengths and weaknesses of response in the event of a bioterrorist attack during the ongoing COVID-19 pandemic have been identified. The scope and importance of international cooperation in the fight against the pandemic is assessed.

Review methods:
The more important literature on bioterrorism, biological weapons and the COVID-19 pandemic, both from earlier work and recent publications, was analyzed, emphasizing new threats and adequate defence against them.

Brief description of the state of knowledge:
The bio-warfare threat and the current COVID 19 pandemic that has hit mankind on a global scale has clearly shown how dangerous biological agents are and what effects they can cause, negatively affecting every sphere of human activity with catastrophic consequences. Data on examples of bioterrorist attacks carried out and research on the development of biological weapons and methods of combating pandemic COVID-19, were reviewed. New threats related to technological development,including those resulting from genetic manipulation, biosynthesis, and modern means of delivery, are pointed out. Attention has been paid to the implications of controlling the proliferation of biological weapons and the issues of international cooperation in the fight against bioterrorism and the COVD-19 pandemic.

Summary:
The lesson learned clearly demonstrates the weakness of states in responding to such threats. The risks of uncontrolled scientific advances are still underestimated. Appropriate international control measures must be taken urgently to prepare for new pandemics, bioterrorist attacks, and the possibility of using modern biological weapons.

 
REFERENCES (56)
1.
Bozue J, Cote Ch, Glass PJ. Medical Aspects of Biological Warfare. Office of the Surgeon General US Army Medical Center. Fort Sam Houston, Texas; 2018.
 
2.
Chomiczewski K, Kocik J, Szkoda MT. Bioterroryzm. Zasady postepowania lekarskiego. Warszawa: PZWL; 2002.
 
3.
Frerichs RL, Salerno RM, Vogel KM, et al. Historical precedence and technical requirements of biological weapons use: A threat assessment. International Security Initiatives Sandia National Laboratories, 2004.
 
4.
Dembek ZF, Pavlin JA, Siwek M. Epidemiology of Biowarfare and Bioterrorism. In: Bozue J, Cote Ch, Glass JP, editors. Medical Aspects of Biological Warfare; 2018. p. 37–69.
 
5.
Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous or Other Gases, and of Bacteriological Methods of Warfare signed at Geneva, 17 June 1925. https://www.un.org/disarmament... wmd/bio/1925-geneva-protocol (access: 2022.01.24).
 
6.
Wheelis M, Rózsa L, Dando M. Deadly Cultures: Biological weapons since 1945. Harvard University Press; 2009.
 
7.
Mierzejewski J, Bartoszcze M. Konsekwencje doświadczeń nad wykorzystaniem Bacillus anthracis jako broni biologicznej. Post Mikrob. 1995; 34: 385–401.
 
8.
The Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, Geneva, Switzerland, 10 April 1972. https:// front.un-arm.org/wp-content/up.... pdf (access: 2022.01.24).
 
9.
Alibek K, Handelman S. Biohazard. Random House New York; 1998.
 
10.
Roffey R, Unge W, Clevström J, Westerdahl KS. Support to threat reduction of the Russian biological weapons legacy – conversion, biodefence and the role of Biopreparat. Swedish Defence Research Agency, NBC Defence; 2003.
 
11.
U.S. Department of State. Adherence to and compliance with arms control, nonproliferation, and disarmament agreements and commitments report. Bureau of Arms Control, Verification and Compliance https://www.state.gov/2021-adh... (access: 2022.01.24).
 
12.
Takahashi H, Keim P, Kaufmann AF, et al. Bacillus anthracis bioterrorism incident, Kameido, Tokyo, 1993. Emerg Infect Dis. 2004; 10(1): 117–120.
 
13.
Australia Group. Common Control List Handbook Volume II: Biological Weapons-Related Common Control Lists, Revision 6, January, 2021. https://www.dfat.gov.au/sites/... control-list-handbook-volume-ii.pdf (access: 2022.01.24).
 
14.
Cieslak TJ, Kortepeter MG, Wojtyk RJ, Jansen HJ, Reyes RA, Smith JO, and the NATO Biomedical Advisory Panel. Beyond the dirty dozen: a matrix methodology for assessing Future Bioweapon Threats. Military Med. 2018; 183: e59-e65.
 
15.
Allswede MP, Binyamin T. Terrorist possession of weaponize plague in North Africa: A forensic epidemiology case study and discussion of principles of Tizi Ouzou, Algeria. Prehosp Disaster Med. 2011; 26,S1: s106. https://doi.org/10.1017/S10490....
 
16.
Łysoń S. Making health policy decisions in the light of the threats of bioterrorism on the example of smallpox vaccination in the United States. PhD Thesis. Kraków: Collegium Medicum. Jagiellonian University; 2007.
 
17.
Edwin S, Roxas-Duncan V, Ceralde A, et al. Biological surety. In: Bozue J, Cote Ch, Glass JP, editors. Medical Aspects of Biological Warfare; 2018. p. 895–914.
 
18.
National Research Council (US) Committee on Research Standards and Practices to Prevent the Destructive Application of Biotechnology. Biotechnology Research in an Age of Terrorism. Washington (DC): National Academies Press (US); 2004. https://doi.org/10.17226/10827.
 
19.
Jackson RJ, Ramsay AJ, Christensen CD, et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol. 2001; 75(3): 1205–1210.
 
20.
Agar SL, Sha J, Foltz SM, et al. Characterization of the rat pneumonia plague model: infection kinetics following aerosolizatiob of Y. pestis CO92. Microbes Infect. 2009; 11(2): 205–214.
 
21.
Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 2002; 9; 297(5583): 1016–8. doi: 10.1126/science.1072266.
 
22.
Shimono N, Morici L, Casali M, Cantrell S. Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. PNAS 2003; 100: 15918–15923.
 
23.
Cunningham ML, Titus RG, Salvatore SJ, Beverly SM. Regulation of differentiation of the infective state of the protozoal parasite Leishmania major bytetrahydrobiopterin. Science. 2001; 292: 285–287.
 
24.
Trevan T. Military Science: The USSR’s deadly secret. Nature. 2012; 489: 364–365. https://doi.org/10.1038/489364....
 
25.
Taubenberger JK. The origin and virulence of the 1918 “Spanish” Influenza Virus. Proc Amer Philos Soc. 2006; 150(1): 86–112.
 
26.
Grabowski ML, Kosińska B, Knap JP, Brydak B. Lethal Spanish influenza Pandemic in Poland. Med Sci Bull. 2017; 23: 4880–4884.
 
27.
Brockmann K. Advances in 3D printing technology: Increasing biological weapon proliferation risks? https://www.sipri.org/ commentary/blog/2019/advances-3d-printing-technology-increasing- biological-weapon-proliferation-risks (access 2022.01.24).
 
28.
Mattox JM. Additive manufacturing and its implications for military ethics. J Mil Ethics. 2013; 12: 225–234. doi: 10.1080/15027570.2013.847534.
 
29.
Bellamy J, Hezbollah ́s UAV biological weapon capability. A game changer. The English Rev. June, 2013.
 
30.
Dembek Z, Kortepeter M, Pavlin J. Discernment between deliberate and natural infectious disease outbreaks. Epidem Infect. 2007; 35(3): 353–371. doi:10.1017/S0950268806007011.
 
31.
ATP-45. Warning and reporting and hazard prediction of chemical, biological, radiological and nuclear incidents (operators manual): ATP 45. Brussels: NATO NSO; 2020.
 
32.
Grunow R, Finke EJ. A procedure for differentiating between intentional release of biological warfare agents and natural outbreaks of disease: its use in analyzing the tularemia outbreak in Kosovo in 1999 and 2000. Clin Microbiol Infect. 2002; 8: 510–521.
 
33.
Solarz J, Młynarczyk M. Wybrane aspekty prognozowania skażeń. Warszawa: Akademia Obrony Narodowej; 2009.
 
34.
World Health Organization. Santé publique et armes chimiques et biologiques: rapport d’ un Groupe de consultants de l’ OMS. Organisation mondiale de la Santé. WHO, 1970. https://apps.who.int/ iris/handle/10665/62904.
 
35.
Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis. 1997; 3(2): 83–94. https://doi.org/10.3201/eid030...
 
36.
WHO Coronavirus disease (COVID-19) advice for the public: Mythbusters https://www.who.int/emergencie... coronavirus-2019/advice-for-public/myth-busters (access: 2022.01.24).
 
37.
WHO Country & Technical Guidance – Coronavirus disease (COVID-19) https://www.who.int/emergencie... coronavirus-2019/technical-guidance (access: 2022.01.24).
 
38.
De Maio G. NATO’s response to COVID-19 lessons for resilience and readiness. Foreign Policy. October 2020; 1–18.
 
39.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181–192.
 
40.
Bakanidze L, Imnadze P, Perkins D. Biosafety and biosecurity as essentials pillars of international health security and cross-cutting elements of biological nonproliferation, BMC Public Health. 2010; 10(Suppl1): S12.
 
41.
World Health Organization. Responsible life sciences research for global health security: A guidance document. Genewa: WHO; 2010.
 
42.
World Health Organization. Laboratory biosecurity guidance: Biorisk management. Genewa: WHO; 2006.
 
43.
Council Regulation (EC) No 428/2009 of 5 May 2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items. Official Journal of the European Union OJ L 134, 29.5.2009.
 
44.
Radosavljevic V. Analysis of COVID-19 outbreak origin in China in 2019 using differentiation method for unusual epidemiological events. Open Med. 2021; 16(1): 955–963. https://doi.org/10.1515.
 
45.
Bloom JD, Chan YA, Baric RS, et al. Investigate the origins of COVID-19. Science 2021; 372(6543): 694. doi:10.1126/science.abj0016.
 
46.
Maxmen A, Mallapaty S. The COVID lab-leak hypothesis: what scientists do and don’t know. Nature. 2021 Jun; 594(7863): 313–315. doi: 10.1038/d41586-021-01529-3.
 
47.
Understanding the Risk of Bat Coronavirus Emergence. Project Number 5R01AI110964-05 https://reporter.nih.gov/searc... xQW6UJmWfUuOV01ntGvLwQ/project-details/9491676 (access: 2022.01.24).
 
48.
Kaina B. On the origin of SARS-CoV-2: Did cell culture experiments lead to increased virulence of the progenitor virus for humans? In Vivo 2021; 35(3): 1313–1326. doi:10.21873/invivo.12384.
 
49.
Sirotkin K, Sirotkin D. Might SARS-CoV-2 have arisen via serial passage through an animal host or cell culture? BioEssays 2020,42:2000091. https://doi.org/10.1002/bies.2....
 
50.
Wade N. Origin of Covid — following the clues, did people or nature open Pandora’s box at Wuhan? https://nicholaswade.medium.co... origin-of-covid-following-the-clues-6f03564c038 (access: 2022.01.24).
 
51.
WHO International Health Regulations. 5th edition. Geneva: WHO; 2005.
 
52.
Holmes BJ. Communicating about emerging infectious diseases: The importance of research. Health Risk Soc. 2008; 10(4): 349–360.
 
53.
Knap JP. Szczególnie niebezpieczne choroby infekcyjne i czynniki infekcyjne – przywlekane do Polski. Próba analizy. In: Konieczny J, editor. Bezpieczeństwo epidemiologiczne. Postępy metodologii badań. Poznań: Wyd. Garmond; 2013. p. 18–33.
 
54.
Świątecka A. Interdisciplinary and international aspects of preparing for an influenza pandemic. An attempt of analysis. Ph D Thesis. Warsaw Medical University; 2014.
 
55.
Mirski T, Bartoszcze M, Bielawska-Drózd A, et al. Review of methods used for identification of biothreat agents in environmental protection and human health aspects. Ann Agric Environ Med. 2014; 21(2): 224– 234.
 
56.
Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC). Official Journal of the European Union. OJ L 262, 17.10.2000, p. 21–45.
 
eISSN:1898-2263
ISSN:1232-1966